NCT01161355View on ClinicalTrials.gov

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Healthy
Interventions
DRUG

AZD9668

Tablets of AZD9668 and IV dose of \[C14\]AZD9668

Trial Locations (2)

Unknown

Research Site, Ruddington

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01161355 - Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject | Biotech Hunter | Biotech Hunter